Your browser doesn't support javascript.
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.
Zhuang, Xiaodong; Tsukuda, Senko; Wrensch, Florian; Wing, Peter A C; Schilling, Mirjam; Harris, James M; Borrmann, Helene; Morgan, Sophie B; Cane, Jennifer L; Mailly, Laurent; Thakur, Nazia; Conceicao, Carina; Sanghani, Harshmeena; Heydmann, Laura; Bach, Charlotte; Ashton, Anna; Walsh, Steven; Tan, Tiong Kit; Schimanski, Lisa; Huang, Kuan-Ying A; Schuster, Catherine; Watashi, Koichi; Hinks, Timothy S C; Jagannath, Aarti; Vausdevan, Sridhar R; Bailey, Dalan; Baumert, Thomas F; McKeating, Jane A.
  • Zhuang X; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Tsukuda S; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wrensch F; Université de Strasbourg, Strasbourg, France and INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
  • Wing PAC; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Schilling M; Chinese Academy of Medical Sciences (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Harris JM; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Borrmann H; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Morgan SB; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Cane JL; Respiratory Medicine Unit and National Institute for Health Research Oxford Biomedical Research Centre, Nuffield Department of Medicine, Experimental Medicine, University of Oxford, UK.
  • Mailly L; Respiratory Medicine Unit and National Institute for Health Research Oxford Biomedical Research Centre, Nuffield Department of Medicine, Experimental Medicine, University of Oxford, UK.
  • Thakur N; Université de Strasbourg, Strasbourg, France and INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
  • Conceicao C; The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey, UK.
  • Sanghani H; The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey, UK.
  • Heydmann L; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Bach C; Université de Strasbourg, Strasbourg, France and INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
  • Ashton A; Université de Strasbourg, Strasbourg, France and INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
  • Walsh S; Department of Pharmacology, University of Oxford, Oxford, UK.
  • Tan TK; Department of Pharmacology, University of Oxford, Oxford, UK.
  • Schimanski L; MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford 17 OX3 9DS, UK.
  • Huang KA; Chinese Academy of Medical Sciences (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Schuster C; MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford 17 OX3 9DS, UK.
  • Watashi K; Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University and Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Hinks TSC; Université de Strasbourg, Strasbourg, France and INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
  • Jagannath A; Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Vausdevan SR; Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan.
  • Bailey D; Respiratory Medicine Unit and National Institute for Health Research Oxford Biomedical Research Centre, Nuffield Department of Medicine, Experimental Medicine, University of Oxford, UK.
  • Baumert TF; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • McKeating JA; Department of Pharmacology, University of Oxford, Oxford, UK.
iScience ; 24(10): 103144, 2021 Oct 22.
Article in English | MEDLINE | ID: covidwho-1428079
ABSTRACT
The coronavirus disease 2019 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus, is a global health issue with unprecedented challenges for public health. SARS-CoV-2 primarily infects cells of the respiratory tract via spike glycoprotein binding to angiotensin-converting enzyme (ACE2). Circadian rhythms coordinate an organism's response to its environment and can regulate host susceptibility to virus infection. We demonstrate that silencing the circadian regulator Bmal1 or treating lung epithelial cells with the REV-ERB agonist SR9009 reduces ACE2 expression and inhibits SARS-CoV-2 entry and replication. Importantly, treating infected cells with SR9009 limits SARS-CoV-2 replication and secretion of infectious particles, showing that post-entry steps in the viral life cycle are influenced by the circadian system. Transcriptome analysis revealed that Bmal1 silencing induced interferon-stimulated gene transcripts in Calu-3 lung epithelial cells, providing a mechanism for the circadian pathway to limit SARS-CoV-2 infection. Our study highlights alternative approaches to understand and improve therapeutic targeting of SARS-CoV-2.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: IScience Year: 2021 Document Type: Article Affiliation country: J.isci.2021.103144

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: IScience Year: 2021 Document Type: Article Affiliation country: J.isci.2021.103144